AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04798248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Momentary Affect Regulation - Safer Sex Intervention (MARSSI)
Description: MARSSI is an individual-level intervention that involves a one-hour manualized session with a sexual reproductive health (SRH) counselor, followed by one-month of daily use of a mobile health app and a final 20-minute booster session with the SRH counselor.
Study NCT04798248 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Podcast Health Group
Description: Participants assigned to the Podcast Health Group will listen to \~20 minute podcast episode put out by the Susan G. Komen Foundation about family history of breast cancer; the podcast does not include information related to the outcomes of interest for the study.
Study NCT06359327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given placebo for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
Study NCT06359327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep19 2 mg
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 2 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
Study NCT06359327 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pep19 5 mg
Description: Subjects will be given an informed consent as per the form submitted to Advarra IRB. 8 randomized subjects will be given 5 mg of Pep19 for 60 days. Placebo will be formulated as a dietary supplement in veggie capsules with microcrystalline cellulose excipient.
Study NCT04714151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.2 mg/day (once daily)
Description: K-877 ER 0.2 mg tablet
Study NCT04714151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 ER 0.4 mg/day (once daily)
Description: K-877 ER 0.4 mg tablet
Study NCT04714151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877 IR 0.2 mg/day (twice daily)
Description: K-877 IR 0.1 mg tablet
Study NCT05585775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: MBCT classes are comprised of weekly, 2.5-hour classes in which participants learn cognitive therapy techniques and practice meditation exercises. Participants will complete group and/or individual orientation to MBCT with the MBCT instructor, 1-2 weeks prior to the first scheduled MBCT class. Additionally, MBCT requires 45-minutes of daily home practice, and a full day, 8-hour silent meditation retreat. MBCT classes are delivered via the protocol and curriculum developed by the MBCT founders. Participants randomized to MBCT will receive 8-weeks of MBCT classes.
Study NCT05585775 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness for Wellbeing
Description: Wellness for Wellbeing will serve as the active control for MBCT. Participants randomized to Wellness for Wellbeing will receive 1-hour group delivered classes, once per week, for 8-weeks. Participants will receive an orientation to Wellness for Wellbeing 1-2 weeks prior to the first class. Classes will be delivered by a research therapist. Topics for Wellness for Wellbeing include: nutrition, caffeine, preventing cancer, diabetes, heart health, sleep, being a smart patient, and complementary and alternative medicine. Wellness for Wellbeing classes are interactive and do not include components designed to impact affective cognition in any way. Because participants may have varying levels of health literacy, the research therapist tailors presentation of the material to the participants' level of knowledge of the topic. Information presented in Wellness for Wellbeing is regularly updated with current health guidelines.
Study NCT05245786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A
Description: Given IV
Study NCT05245786 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Imaging Technique
Description: Undergo imaging
Study NCT04785989 — intervention group
Intervention type: OTHER
Intervention: [U-13C]glucose
Description: \[U-13C\]glucose will be administered as a bolus of 8 g (grams) over 10 minutes followed by 8 g/hour continuous infusion over 2 hours . This infusion rate will allow glucose tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
Study NCT04785989 — intervention group
Intervention type: OTHER
Intervention: [13C5]glutamine
Description: 6mg/kg of body weight of \[13C5\]glutamine will be administered as a bolus over 10 minutes (± 1 minute) followed by 6mg/kg/hr body weight continuous infusion for 2 hours through a peripheral IV catheter/line. This infusion rate will allow glutamine tracer to reach sufficient enrichment without causing significant metabolic perturbation such as hyperglycemia.
Study NCT06426602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mindBEAGLE daily device use
Description: If participants are considered responsive, they will continue to use the device daily for the remainder of their stay at inpatient rehab, or until they regain consciousness.
Study NCT06288932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF) Treatment
Description: The first-line treatment of immune thrombocytopenia purpura with Mycophenolate Mofetil produced a significant response, a lowered likelihood of refractory ITP, a better outcome, and less financial burden.
Study NCT05638945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ED Delirium Screening and Detection Program (ED-DDP)
Description: The intervention arm will have standardized delirium screening by nurses using the brief confusion assessment method (bCAM) in the EHR and will receive the ED-DDP. The ED-DDP will consist of: 1) a multicomponent 1-day delirium champion workshop; 2) real-time direct observation/training via telehealth (tele-training); and 3) training of nurses by champions. Champions will participate in a 1-day workshop, consisting of patient testimonials, small group discussions, delirium and screening tool use (didactics), and role-playing. Following the workshop, champions will receive 3 tele-training sessions; 2 to provide direct observation/feedback while the champion performs a bedside delirium screen, and 1 to provide direct observation/feedback of the champion providing training to the nurse. Once delirium champions complete training, they will provide bedside delirium training for all ED nurses.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2110
Description: TNX-2110 represents epitopes of multiple proteins from SARS-CoV-2 and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2120
Description: TNX-2120 represents the spike protein and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: TNX-2130
Description: TNX-2130 represents non-spike proteins and is administered intradermally.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: CANDIN
Description: Candida albicans antigens to be administered intradermally as a positive control.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
Study NCT05216510 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Diluent
Description: Diluent consists of phosphate buffer, polysorbate 20 and mannitol and will be administered intradermally as a negative control.
Study NCT06538558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezampanel
Description: Study drug will be given intravenously (mg/kg) at 6 timepoints during study participation
Study NCT06538558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be given intravenously (mg/kg) at 6 timepoints during study participation to a subset of participants in each cohort.
Study NCT06368089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) group
Description: The IMT group receives inspiratory muscle training of 50%MIP, 6 breaths/set 10 sets/day for 7 days combined with conventional chest physiotherapy including; percussion, vibration, postural draining, positioning, and passive range of motion.
Study NCT06368089 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization (EM) group
Description: The ER group received active exercise in sitting, standing, and marching 30 minutes/day for 7 days with conventional chest physical therapy
Study NCT06522295 — intervention group
Intervention type: DEVICE
Intervention: ultrasonography
Description: Ultrasonographic Measurement of Optic Nerve Sheath Diameter
Study NCT06079320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sisunatovir
Description: Participants will receive tablets from Day 1 to Day 5
Study NCT06079320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo tablets from Day 1 to Day 5
Study NCT05311319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+TQB2450+Anlotinib
Description: HAIC: FOLFOX for 24hour perfusion chemotherapy. Anlotinib: 10mg orally daily on day 1 to 14 of a 21-day cycle. TQB2450: 1200 milligrams (mg) administered intravenously (IV) on Day 1 of each 21-day cycle.
Study NCT05482399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Statin discontinuation
Description: Statin therapy will be stopped. Additional lipid-lowering medication lowering LDL cholesterol will also be stopped.
Study NCT06499246 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Parathyroid
Description: Once a potential donor becomes available, the transplant team will assess if the donor is a match for our study participant using standardized transplantation protocols that include serology blood tests completed in the pre-operative setting. If the donor is a match, the procurement team will procure all parathyroid tissue using standard surgical techniques. The specimen will be kept in organ preservation solution for transport and transported to the operating room. The recipient (study participant) will be admitted to the hospital under and taken to the operating room for the surgical procedure. Once the procurement team arrives with the parathyroid tissue the procedure will be performed under local anesthesia using a well-established technique, for parathyroid auto transplant, of implanting parathyroid tissue in the non-dominant brachioradialis muscle. Immunosuppression medication protocols will be initiated.
Study NCT04970342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Lactose) Capsule
Description: Single dose on two of the three study visits, orally administered 40 minutes prior to cannabis dose
Study NCT04970342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.75 mg Alprazolam Capsule
Description: Single dose on one of the three study visits, orally administered 40 minutes prior to cannabis dose
Study NCT04970342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (6.18% THC / <0.025% CBD)
Description: Cannabis vapor is produced from 500 mg of dried plant material (6.18% THC / \<0.025% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose on one of the three study visits.
Study NCT04970342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (0%/ THC / 0% CBD)
Description: Cannabis vapor is produced from 500 mg of dried plant material (0% THC / 0% CBD). Subjects will inhale using the Foltin Puff Procedure over 10 minutes. Single inflated bag/dose consumed via inhalation 40 minutes after alprazolam dose at two of the three study visits.
Study NCT06206603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intestinal biopsies
Description: Approximately 6 biopsies (each around 2-3mm in size) are taken from the polyp or cancer, as well as adjacent healthy intestinal mucosa, during a scheduled colonoscopy. For healthy controls, around 6 biopsies are taken from the healthy intestinal mucosa. The intestinal biopsies are frozen at -80 degrees Celsius.
Study NCT06206603 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: A venous blood sample (10ml) will be taken in connection with the colonoscopy. Patients typically receive an intravenous needle for the administration of sedatives and pain-relieving medications during the colonoscopy, so the current blood sample does not cause any additional needle sticks or discomfort for the patient. The blood sample is centrifuged, and the plasma is frozen at -80 degrees Celsius.
Study NCT04882917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4076
Description: M4076 will be administered orally, in Part 1A and Part 1B.
Study NCT06166784 — intervention group
Intervention type: DEVICE
Intervention: Mectascrew B
Description: reconstruction of ACL or PCL rupture
Study NCT06174636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of abdominal weight
Description: Application of variable weight on the abdomen to reach a 5 mmHg increase in IAP
Study NCT06263556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises
Description: Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day
Study NCT06263556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation
Description: Patients in TTSN group will receive posterior tibial nerve stimulation based on the protocol explained before.
Study NCT06263556 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Patients in sham stimulation group will receive sham stimulation based on the protocol explained before.
Study NCT05174065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Oral tablets
Study NCT05174065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study NCT04727424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spirulin Platensis
Description: Two tablets every 12 hours since randomization through day 09 following randomization
Study NCT04727424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Spirulin Platensis
Description: Two tablets every 12 hours since randomization through day 09 following randomization
Study NCT04727424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Powder
Description: One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.
Study NCT04727424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Budesonide Powder
Description: One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.
Study NCT04727424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine 20 MG
Description: Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.
Study NCT04727424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoxetine 20 MG
Description: Two Fluoxetine tablets every day starting just after randomization through day 07.~PLUS~01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.
Study NCT04727424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablets (10-day schedule):~Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)~PLUS~Placebo Inhalation Therapy:~One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days~OR~Paracetamol (07-day schedule - active comparator):~Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm)~OR~Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)
Study NCT05250141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa 250mg and Carbidopa 25mg Test Drug tablet
Description: Investigational Medicinal Product
Study NCT05250141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa 250mg and Carbidopa 25mg Referent Product tablet
Description: Sinemet (Savio Industrial S.R.L, Brazil)
Study NCT05093972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
Study NCT05093972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ulonivirine
Description: Four ulonivirine 100 mg tablets (total dose 400 mg) taken by mouth.
Study NCT05209035 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone 50mg daily
Study NCT05209035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch 50mg
Study NCT05925582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vestibular based exercise program
Description: this group's participants will involve in vestibular based exercise program
Study NCT05925582 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: calisthenic based exercise program
Description: this group's participants will involve in calisthenic based exercise program
Study NCT06130683 — intervention group
Intervention type: OTHER
Intervention: Single-cell sequencing
Description: Single-cell sequencing technology can reveal the gene structure and gene expression status of individual cells, reflecting the heterogeneity between cells.
Study NCT06211712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Human Urinary Kallidinogenase
Description: Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Study NCT06211712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Before the first day of endovascular therapy (non-bridging), dissolve placebo in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.